[18F]Florbetazine ([18F]92) for Beta Amyloid PET Imaging in Alzheimer's Disease - Trial NCT06141356

Timeline & Enrollment

Primary Outcome

The non-displacable binding potential (BPND) of [18F]Florbetazine in healthy participants and patients with probable AD,The distribution volume ratio (DVR) of [18F]Florbetazine in healthy participants and patients with probable AD,Comparison of the cortical and white matter binding of [18F]Florbetazine ([18F]92) with [11C]PIB in healthy participants and patients with cognitive decline

Summary

[18F]Florbetazine ([18F]92) is a molecularly targeted imaging agent for Aβ protein with a
 novel diaryl-azine scaffold. It has shown specific binding affinity to Aβ aggregates in
 postmortem human AD brains and excellent brain pharmacokinetic properties with little
 non-specific retention in white matter in animal studies and a limited number of patients
 with Alzheimer's Disease (AD).
 
 The purpose of the current study is to examine the binding properties of [18F]Florbetazine in
 human subjects and to compare the cortical and white matter binding with [11C]PiB or
 [18F]Florbetapir in the same subjects.
 
 Imaging of the brain will be completed in healthy adult normal control participants and
 participants with cognitive impairment (including probable AD and dementia due to other
 conditions) to characterize [18F]Florbetazine uptake in the brain and its binding properties.
 [11C]PIB or [18F]Florbetapir PET imaging along with MRI will be completed in the same
 participants and the data will be compared with 18F-[18F]Florbetazine.

ICD-10 Classifications